Arctic Securities acted as Joint Bookrunner in relation to the Private Placement in BerGenBio ASA. Through the Offering, BerGenBio raised gross proceeds of NOK 500 million, which will be used to take full advantage of clinical development opportunities stemming from the Company’s technology and to progress readiness for early commercialisation possibilities, as well as for general corporate purposes.
BerGenBio is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class drugs for most aggressive cancers. Ongoing international clinical trials with the Company's lead product BGB324 is in patients with lung cancer and leukaemia. The Company is a world leader in understanding the central role of AXL kinase in driving immune evasion, drug resistance and metastasis, key traits of aggressive cancer and the cause of the majority of cancer-related deaths.
We are grateful for the continued vote of confidence and congratulate on the successful transaction!